AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 38614379 — intervention group
Group type: EXPERIMENTAL
Intervention: Core Stabilization Exercise Training (CSET)
Number of subjects: 51
Study 38614379 — intervention group
Group type: COMPARATOR
Intervention: Control group (no exercise program)
Number of subjects: 51
Study 38614445 — intervention group
Group type: EXPERIMENTAL
Intervention: Telehealth Oncofertility Care (TOC) intervention
Number of subjects: 20
Study 38614445 — intervention group
Group type: COMPARATOR
Intervention: Usual care control condition
Number of subjects: 20
Study 38614447 — intervention group
Group type: EXPERIMENTAL
Intervention: bCBCT augmented with intranasal oxytocin (40 international units administered 30 min before each session)
Number of subjects: 120
Study 38614447 — intervention group
Group type: COMPARATOR
Intervention: bCBCT plus placebo
Number of subjects: 120
Study 38614447 — intervention group
Group type: EXPERIMENTAL
Intervention: bCBCT augmented with intranasal oxytocin
Number of subjects: 120
Study 38614630 — intervention group
Group type: EXPERIMENTAL
Intervention: Liquefied petroleum gas (LPG) stove, continuous fuel delivery, and behavioural messaging
Number of subjects: 3200
Study 38614630 — intervention group
Group type: COMPARATOR
Intervention: Usual cooking with biomass
Number of subjects: 3200
Study 38614631 — intervention group
Group type: EXPERIMENTAL
Intervention: Euvichol-S (two 1.5 mL doses)
Number of subjects: 2529
Study 38614631 — intervention group
Group type: COMPARATOR
Intervention: Shanchol (active control)
Number of subjects: 2529
Study 38614631 — intervention group
Group type: EXPERIMENTAL
Intervention: Euvichol-S
Number of subjects: 2529
Study 38614631 — intervention group
Group type: COMPARATOR
Intervention: Shanchol
Number of subjects: 2529
Study 38614954 — intervention group
Group type: EXPERIMENTAL
Intervention: TBE vaccine (0.5-mL for adults, 0.25-mL for pediatric) administered at 3 visits.
Number of subjects: 165
Study 38615067 — intervention group
Group type: EXPERIMENTAL
Intervention: Letermovir 480 mg daily orally for 28 weeks
Number of subjects: 22
Study 38615070 — intervention group
Group type: EXPERIMENTAL
Intervention: Seasonal vaccination
Number of subjects: 0
Study 38615070 — intervention group
Group type: COMPARATOR
Intervention: Unvaccinated uninfected children
Number of subjects: 0
Study 38615070 — intervention group
Group type: EXPERIMENTAL
Intervention: Children infected after seasonal vaccination
Number of subjects: 0
Study 38615070 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline hemagglutination antibody inhibition
Number of subjects: 0
Study 38615472 — intervention group
Group type: EXPERIMENTAL
Intervention: Temozolomide 75 mg/m² given every other week (one week on/one week off)
Number of subjects: 38
Study 38615472 — intervention group
Group type: EXPERIMENTAL
Intervention: Temozolomide 75 mg/m²
Number of subjects: 38
Study 38615657 — intervention group
Group type: EXPERIMENTAL
Intervention: pegcetacoplan
Number of subjects: 10
Study 38615657 — intervention group
Group type: COMPARATOR
Intervention: eculizumab
Number of subjects: 10
Study 38615662 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT)
Number of subjects: 210
Study 38615673 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular 85 μg CTH522-CAF01, two boosters at day 28 and 112, and a mucosal recall with either placebo or CTH522 topical ocularly at day 140 (Group A)
Number of subjects: 65
Study 38615673 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular 85 μg CTH522-CAF01, two boosters at day 28 and 112 with additional topical ocular administration of CTH522 (Group B)
Number of subjects: 65
Study 38615673 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular 85 μg CTH522-CAF01, two boosters at day 28 and 112 with additional intradermal administration of CTH522 (Group C)
Number of subjects: 65
Study 38615673 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular 15 μg CTH522-CAF01, two boosters at day 28 and 112 (Group D)
Number of subjects: 65
Study 38615673 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular 85 μg CTH522-CAF09b, two boosters at day 28 and 112 (Group E)
Number of subjects: 65
Study 38615673 — intervention group
Group type: COMPARATOR
Intervention: Intramuscular placebo (Group F)
Number of subjects: 65
Study 38615750 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient navigation program delivered remotely by a trained lay-person from a community-based organization.
Number of subjects: 0
Study 38615750 — intervention group
Group type: COMPARATOR
Intervention: Standard of care control.
Number of subjects: 0
Study 38615899 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance exercise training (RET), 16-week, twice-weekly, whole-body intervention
Number of subjects: 10
Study 38615899 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance exercise training (RET)
Number of subjects: 10
Study 38616018 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthy older adults
Number of subjects: 227
Study 38616018 — intervention group
Group type: EXPERIMENTAL
Intervention: Older adults with COPD
Number of subjects: 227
Study 38616018 — intervention group
Group type: COMPARATOR
Intervention: Overall comparison between healthy and COPD groups
Number of subjects: 227
Study 38616018 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall population
Number of subjects: 227
Study 38616018 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall conclusion
Number of subjects: 227
Study 38616241 — intervention group
Group type: EXPERIMENTAL
Intervention: Valoctocogene roxaparvovec
Number of subjects: 294
Study 38616241 — intervention group
Group type: COMPARATOR
Intervention: Prophylactic factor VIII (FVIII)
Number of subjects: 294
Study 38616242 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote Ischemic Conditioning (RIC) - four cycles of 5 min of pressurization (about 200 mmHg) and 5 min of rest in the 3 days before and 7 days after surgery.
Number of subjects: 648
Study 38616242 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified in detail).
Number of subjects: 648
Study 38616276 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality improvement collaborative across 10 UK sites
Number of subjects: 50
Study 38616276 — intervention group
Group type: EXPERIMENTAL
Intervention: Multidisciplinary team (MDT) discussions
Number of subjects: 50
Study 38616276 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality assessment of long covid services
Number of subjects: 50
Study 38616275 — intervention group
Group type: EXPERIMENTAL
Intervention: Portable pedal machines (PPMs) for 12 weeks
Number of subjects: 40
Study 38616275 — intervention group
Group type: COMPARATOR
Intervention: Normal-desk (control group)
Number of subjects: 40
Study 38616308 — intervention group
Group type: EXPERIMENTAL
Intervention: Dasatinib plus low-intensity chemotherapy for one month followed by dasatinib monotherapy for two months
Number of subjects: 22
Study 38616308 — intervention group
Group type: EXPERIMENTAL
Intervention: Dasatinib-based low-intensity chemotherapy
Number of subjects: 22
Study 38616411 — intervention group
Group type: EXPERIMENTAL
Intervention: BPL-003 (5-methoxy-DMT) at doses of 1-12 mg
Number of subjects: 44
Study 38616411 — intervention group
Group type: EXPERIMENTAL
Intervention: BPL-003 (5-methoxy-DMT) at doses of 10 and 12 mg
Number of subjects: 44
Study 38616411 — intervention group
Group type: EXPERIMENTAL
Intervention: BPL-003 (5-methoxy-DMT)
Number of subjects: 44
Study 38616438 — intervention group
Group type: EXPERIMENTAL
Intervention: RSVpreF vaccine (120-µg injection)
Number of subjects: 992
Study 38616564 — intervention group
Group type: EXPERIMENTAL
Intervention: Amoxicillin
Number of subjects: 1000
Study 38616564 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1000
Study 38616571 — intervention group
Group type: EXPERIMENTAL
Intervention: Urine drug screening (UDS) based definitions for treatment success
Number of subjects: 2492
Study 38616781 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous (SC) administration of natalizumab
Number of subjects: 262
Study 38616781 — intervention group
Group type: COMPARATOR
Intervention: Intravenous (IV) administration of natalizumab
Number of subjects: 262
Study 38617387 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapist-guided internet-delivered cognitive behavioural therapy (ICBT) for 12 weeks
Number of subjects: 83
Study 38617471 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined pre- and intra-operative nomogram
Number of subjects: 327
Study 38617471 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-operative nomogram
Number of subjects: 327
Study 38617471 — intervention group
Group type: COMPARATOR
Intervention: Conventional predictive models
Number of subjects: 327
Study 38617471 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-operative variables (HBV-DNA level, ICG-R15, prothrombin time, CSS) and intra-operative variable (DSM)
Number of subjects: 327
Study 38617555 — intervention group
Group type: EXPERIMENTAL
Intervention: Caregiver support, burden, grief, self-efficacy, depression, quality of life, and coping measures.
Number of subjects: 143
Study 38617555 — intervention group
Group type: EXPERIMENTAL
Intervention: Caregiver concerns regarding planning for the future and prioritizing the needs of the person with DLB over their own.
Number of subjects: 143
Study 38617555 — intervention group
Group type: EXPERIMENTAL
Intervention: Satisfaction with medical team support.
Number of subjects: 143
Study 38617566 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical activity (60 min treadmill walk)
Number of subjects: 200
Study 38617588 — intervention group
Group type: EXPERIMENTAL
Intervention: WATCHMAN FLX Pro (WFP) implantation
Number of subjects: 1
Study 38617599 — intervention group
Group type: EXPERIMENTAL
Intervention: Capmatinib 400 mg bid plus spartalizumab 300 mg q3w
Number of subjects: 62
Study 38617599 — intervention group
Group type: COMPARATOR
Intervention: Spartalizumab alone
Number of subjects: 62
Study 38617784 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous lidocaine (1.5 mg/kg bolus 30 minutes before incision, followed by continuous infusion of 3.0 mg/kg/hour until 2 hours after skin closure)
Number of subjects: 52
Study 38617784 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52
Study 38618141 — intervention group
Group type: EXPERIMENTAL
Intervention: RENEW intervention (peer health-coached resilience-building energy management)
Number of subjects: 21
Study 38618141 — intervention group
Group type: EXPERIMENTAL
Intervention: RENEW intervention
Number of subjects: 21
Study 38618202 — intervention group
Group type: EXPERIMENTAL
Intervention: GST-HG171 (150 mg) plus Ritonavir (100 mg)
Number of subjects: 1246
Study 38618202 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1246
Study 38618203 — intervention group
Group type: EXPERIMENTAL
Intervention: Camrelizumab, nedaplatin, albumin paclitaxel, and apatinib (2-3 cycles, every 14 days)
Number of subjects: 42
Study 38618203 — intervention group
Group type: EXPERIMENTAL
Intervention: Camrelizumab, nedaplatin, albumin paclitaxel, and apatinib
Number of subjects: 42
Study 38618204 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexfadrostat phosphate 4, 8, or 12 mg once daily for 8 weeks
Number of subjects: 35
Study 38618204 — intervention group
Group type: COMPARATOR
Intervention: Placebo (during the 2-week single-blind placebo run-in period and 2-week single-blind placebo withdrawal period)
Number of subjects: 35
Study 38618545 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (specific diets given orally and in writing)
Number of subjects: 210
Study 38618545 — intervention group
Group type: COMPARATOR
Intervention: Control group (usual approach)
Number of subjects: 210
Study 38618548 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet-related mobile app
Number of subjects: 88
Study 38618550 — intervention group
Group type: EXPERIMENTAL
Intervention: 36 g erythritol daily for 5 weeks
Number of subjects: 42
Study 38618550 — intervention group
Group type: EXPERIMENTAL
Intervention: 24 g xylitol daily for 5 weeks
Number of subjects: 42
Study 38618550 — intervention group
Group type: COMPARATOR
Intervention: No substance (control) for 5 weeks
Number of subjects: 42
Study 38619037 — intervention group
Group type: EXPERIMENTAL
Intervention: Teriflunomide (14 mg adult-equivalent dose)
Number of subjects: 0
Study 38619037 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 38619037 — intervention group
Group type: EXPERIMENTAL
Intervention: Teriflunomide
Number of subjects: 0
Study 38619114 — intervention group
Group type: EXPERIMENTAL
Intervention: Breath analysis
Number of subjects: 2258
Study 38619114 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional upper endoscopy
Number of subjects: 2258
Study 38619114 — intervention group
Group type: EXPERIMENTAL
Intervention: Ingestible cell collection device
Number of subjects: 2258
Study 38619114 — intervention group
Group type: EXPERIMENTAL
Intervention: Transnasal endoscopy
Number of subjects: 2258
Study 38619114 — intervention group
Group type: EXPERIMENTAL
Intervention: General screening preferences
Number of subjects: 2258
Study 38619114 — intervention group
Group type: EXPERIMENTAL
Intervention: General preferences for invitation method
Number of subjects: 2258
Study 38619114 — intervention group
Group type: EXPERIMENTAL
Intervention: General preferences for discussion
Number of subjects: 2258
Study 38619136 — intervention group
Group type: EXPERIMENTAL
Intervention: Clip anchoring (clip group)
Number of subjects: 180
Study 38619136 — intervention group
Group type: COMPARATOR
Intervention: No clip anchoring (control group)
Number of subjects: 180
Study 38619178 — intervention group
Group type: EXPERIMENTAL
Intervention: sirolimus gel
Number of subjects: 62
Study 38619178 — intervention group
Group type: COMPARATOR
Intervention: placebo gel
Number of subjects: 62
Study 38619626 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic ventral mesh rectopexy (LVMR)
Number of subjects: 330
Study 38619626 — intervention group
Group type: COMPARATOR
Intervention: Perineal stapler resection (PSR)
Number of subjects: 330
Study 38619649 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticagrelor
Number of subjects: 580
Study 38619649 — intervention group
Group type: COMPARATOR
Intervention: Clopidogrel
Number of subjects: 580
Study 38619715 — intervention group
Group type: EXPERIMENTAL
Intervention: Smartphone photoplethysmography (PPG) application for screening clinical AF
Number of subjects: 0
Study 38619715 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral anticoagulation (OAC)
Number of subjects: 0
Study 38619715 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard laboratory testing and ABC-bleeding risk score
Number of subjects: 0
Study 38619715 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive geriatric assessment and frailty index calculation
Number of subjects: 0
Study 38619713 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous monitoring using a wearable sensor
Number of subjects: 400
Study 38619713 — intervention group
Group type: COMPARATOR
Intervention: Usual care (Control)
Number of subjects: 400
Study 38619713 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous monitoring
Number of subjects: 400
Study 38619714 — intervention group
Group type: EXPERIMENTAL
Intervention: Heart failure (HF) defined as left ventricular ejection fraction (LVEF) < 55% or a history of HF on admission
Number of subjects: 2562
Study 38619714 — intervention group
Group type: COMPARATOR
Intervention: Non-heart failure patients
Number of subjects: 2562
Study 38619783 — intervention group
Group type: EXPERIMENTAL
Intervention: Cerebral autoregulation (CA) impairment assessment using inflatable leg recovery boots
Number of subjects: 29
Study 38619783 — intervention group
Group type: COMPARATOR
Intervention: Healthy volunteers (control group)
Number of subjects: 29
Study 38619824 — intervention group
Group type: EXPERIMENTAL
Intervention: Electronic health record-based population health management intervention
Number of subjects: 1596
Study 38619824 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 1596
Study 38619842 — intervention group
Group type: EXPERIMENTAL
Intervention: LLD-CBT
Number of subjects: 251
Study 38619842 — intervention group
Group type: COMPARATOR
Intervention: SUI
Number of subjects: 251
Study 38619842 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 251
Study 38619854 — intervention group
Group type: EXPERIMENTAL
Intervention: ESC care approach
Number of subjects: 463
Study 38620056 — intervention group
Group type: EXPERIMENTAL
Intervention: FlexHD prophylactic biological mesh using sublay intraperitoneal technique
Number of subjects: 146
Study 38620056 — intervention group
Group type: COMPARATOR
Intervention: Standard IC
Number of subjects: 146
Study 38620056 — intervention group
Group type: EXPERIMENTAL
Intervention: FlexHD prophylactic biological mesh
Number of subjects: 146
Study 38620072 — intervention group
Group type: EXPERIMENTAL
Intervention: Acalabrutinib, venetoclax, and obinutuzumab
Number of subjects: 45
Study 38620092 — intervention group
Group type: EXPERIMENTAL
Intervention: Targeted drugs
Number of subjects: 2247
Study 38620092 — intervention group
Group type: COMPARATOR
Intervention: Chemoimmunotherapy
Number of subjects: 2247
Study 38620092 — intervention group
Group type: COMPARATOR
Intervention: Matched-pair analysis of targeted therapies vs chemoimmunotherapy
Number of subjects: 2247
Study 38621163 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-sex schools
Number of subjects: 34489
Study 38621163 — intervention group
Group type: EXPERIMENTAL
Intervention: Boarding schools
Number of subjects: 34489
Study 38621163 — intervention group
Group type: EXPERIMENTAL
Intervention: Government schools
Number of subjects: 34489
Study 38621162 — intervention group
Group type: EXPERIMENTAL
Intervention: BioFire Pneumonia plus Panel
Number of subjects: 36
Study 38621162 — intervention group
Group type: COMPARATOR
Intervention: Reference standard culturing with antimicrobial susceptibility testing
Number of subjects: 36
Study 38621178 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose atropine (various concentrations)
Number of subjects: 0
Study 38621393 — intervention group
Group type: EXPERIMENTAL
Intervention: Bictegravir (30 mg), Emtricitabine (120 mg), Tenofovir Alafenamide (15 mg) once daily
Number of subjects: 22
Study 38621393 — intervention group
Group type: EXPERIMENTAL
Intervention: Bictegravir (50 mg), Emtricitabine (200 mg), Tenofovir Alafenamide (25 mg) upon attaining a bodyweight of at least 25 kg
Number of subjects: 22
Study 38621400 — intervention group
Group type: EXPERIMENTAL
Intervention: Enzalutamide plus lutetium-177
Number of subjects: 162
Study 38621400 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 162
Study 38621405 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerosol-inhaled live-attenuated Mycobacterium bovis BCG (BCG Danish strain and BCG Bulgaria strain)
Number of subjects: 43
Study 38621405 — intervention group
Group type: COMPARATOR
Intervention: Intradermally administered BCG
Number of subjects: 43
Study 38621575 — intervention group
Group type: EXPERIMENTAL
Intervention: Edetate disodium (EDTA) chelation therapy
Number of subjects: 1000
Study 38621575 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1000
Study 38621624 — intervention group
Group type: EXPERIMENTAL
Intervention: SQ-LNS containing 15 mg zinc from ≥3 months before conception (preconception, arm 1)
Number of subjects: 100
Study 38621624 — intervention group
Group type: EXPERIMENTAL
Intervention: SQ-LNS containing 15 mg zinc from ∼12 weeks gestation through delivery (early pregnancy, arm 2)
Number of subjects: 100
Study 38621624 — intervention group
Group type: COMPARATOR
Intervention: Control group (no zinc supplementation, arm 3)
Number of subjects: 100
Study 38621633 — intervention group
Group type: EXPERIMENTAL
Intervention: ADPKD individuals
Number of subjects: 20
Study 38621793 — intervention group
Group type: EXPERIMENTAL
Intervention: UPA 15 mg QD
Number of subjects: 611
Study 38621793 — intervention group
Group type: EXPERIMENTAL
Intervention: UPA 30 mg QD
Number of subjects: 611
Study 38621793 — intervention group
Group type: COMPARATOR
Intervention: Placebo (initial randomization)
Number of subjects: 611
Study 38621793 — intervention group
Group type: EXPERIMENTAL
Intervention: UPA 15 mg QD and UPA 30 mg QD
Number of subjects: 611
Study 38621793 — intervention group
Group type: EXPERIMENTAL
Intervention: TEAEs
Number of subjects: 611
Study 38621924 — intervention group
Group type: EXPERIMENTAL
Intervention: Yaq-001
Number of subjects: 0
Study 38622106 — intervention group
Group type: EXPERIMENTAL
Intervention: Thoracic ultrasound (TUS)
Number of subjects: 80
Study 38622109 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer-led symptom management intervention
Number of subjects: 173
Study 38622330 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranibizumab 0.5 or 2.0 mg monthly or as needed (HARBOR)
Number of subjects: 173
Study 38622330 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranibizumab 0.5 or 2.0 mg as needed (READ-3)
Number of subjects: 173
Study 38622334 — intervention group
Group type: EXPERIMENTAL
Intervention: CCEF group (biophysical stimulation with a CCEF device for 8 hours per day for 60 days)
Number of subjects: 66
Study 38622334 — intervention group
Group type: EXPERIMENTAL
Intervention: CCEF group
Number of subjects: 66
Study 38622334 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 66
Study 38622370 — intervention group
Group type: EXPERIMENTAL
Intervention: Eosinophil recovery within 6 days after surgery
Number of subjects: 274
Study 38622370 — intervention group
Group type: COMPARATOR
Intervention: Eosinophil recovery requiring more than 6 days
Number of subjects: 274
Study 38622445 — intervention group
Group type: EXPERIMENTAL
Intervention: PIVKA-II combined with alpha-fetoprotein (AFP)
Number of subjects: 0
Study 38622445 — intervention group
Group type: COMPARATOR
Intervention: Control group (Group C)
Number of subjects: 0
Study 38622456 — intervention group
Group type: EXPERIMENTAL
Intervention: Pegsitacianine, administered intravenously at 1 mg/kg 24-72 hours before surgery
Number of subjects: 50
Study 38622456 — intervention group
Group type: EXPERIMENTAL
Intervention: Pegsitacianine
Number of subjects: 50
Study 38622488 — intervention group
Group type: EXPERIMENTAL
Intervention: Lumbar Drainage (LD)
Number of subjects: 287
Study 38622488 — intervention group
Group type: COMPARATOR
Intervention: External Ventricular Drainage (EVD)
Number of subjects: 287
Study 38622520 — intervention group
Group type: COMPARATOR
Intervention: Standard asthma diagnostic work-up (spirometry with reversibility and BPT)
Number of subjects: 171
Study 38622520 — intervention group
Group type: EXPERIMENTAL
Intervention: New asthma diagnostics work-up (FeNO-test as an intermediate step)
Number of subjects: 171
Study 38622520 — intervention group
Group type: EXPERIMENTAL
Intervention: FeNO-test
Number of subjects: 171